At the recent Microbiology Society Annual Conference (10–12 April, Birmingham, UK) we spoke to Mark Wass about his work on Ebolaviruses in which he’s delved into the molecular determinants of the virus’s pathogenicity.
A new gene identified in P. aeruginosa could act as a prognostic biomarker and treatment target for patients with bloodstream infections.
Horizontal gene transfer plagues the control of multi-drug resistant infections, but how exactly are genes transferred and can we stop them? In a recent Cell paper, Rubio-Cosials and colleagues detail the biochemical events leading up to the transfer of transposons carrying antibiotic resistance genes.
In this infographic we take a look at the diagnostics currently in the pipeline for tuberculosis, highlighting the stage of development and intended use.
A proof-of-concept study has demonstrated promise for a new vaccine production platform, which was used to build a prototype synthetic flu vaccine.
This research, published in Future Microbiology, screens host proteins for those that interact with EspF via flow cytometry and high-throughput screening to try and shed light on how EspF affects host cells to induce colitis and even colorectal carcinogenesis.
Mark Blaskovich gives us his thoughts on a recent study he led, published in Nature Communications, where the team re-engineered existing antibiotics to make them more powerful.
Researchers have identified that the Ebola virus recruits a host enzyme, PP2A-B56, for replication, demonstrating that inhibiting this pathway could be a target for drug discovery.
Researchers have established a map of protein interactions for the replication machinery of chronic viruses, shedding insight into viral strategies and uncovering potential drug targets.
Scientists have revealed proteins, termed RIFINs, expressed on the surface of infected erythrocytes that may help the malaria parasite to suppress the host immune response, leading to severe infection.
